The Met receptor tyrosine kinase is the prototypic member of a small subfamily of growth factor receptors that when activated induce mitogenic, motogenic, and morphogenic cellular responses. The ...

The focus of this review is on the development of small molecule tyrosine kinase inhibitors, and does not extend to other approaches that could be applied to disrupt the same pathways in clinical ...

It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or ...

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq) -- as well as three neonatal fragment ...

It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or ...

Nurix Therapeutics shows strong BTK degrader data and key pharma ties, with risks but solid long-term potential. Find out why ...

It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or ...

The combination of cabozantinib and atezolizumab appeared more effective than switching ARPI therapy in patients with mCRPC and extrapelvic soft-tissue metastases.

The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, targeted therapies, and surgery techniques.

HER2 tumor marker tests are used to determine whether breast cancer is HER2 positive or negative. A person is a candidate for ...

Currently dopamine replacement medications, like levodopa and dopamine agonists, are the primary treatment for Parkinson's ...

Waldenstrom Macroglobulinemia sees growing innovation as next-gen BTK inhibitors and novel therapies aim to overcome resistance and reshape treatment pathways. BTK inhibitors laid the groundwork, but ...